ENCORE about translational research in the journal ‘Kinderarts & Samenleving’
Recent werd in het verenigingsmagazine Kinderarts & Samenleving een artikel gepubliceerd waarin kinderarts-EAA Karen Bindels-de Heus en Hoofd ENCORE-onderzoek Prof. Dr. Ype Elgersma vertellen over translationeel onderzoek aan zeldzame genetische aandoeningen bij ENCORE.
Continue ReadingProf.dr. Ype Elgersma tells in the Belgian newspaper about gene therapy for Angelman Syndrome
Prof.dr. Ype Elgersma, head of ENCORE research, was recently interviewed by the Belgian newspaper ‘De Standaard’ about the potential of new gene therapies as a treatment for congenital brain disorders.
Continue ReadingThe TRAIN-study
In the TRAIN-study, we will conduct a study with trametinib in adult NF1 patients with plexiform neurofibromas that cause complaints.
Continue ReadingENCORE and NFVN organize the NF2020 conference!
The NF2020 conference organized by ENCORE in collaboration with NFVN will take place on 10, 11 and 12 December.
Continue ReadingSPECIAL X
Research on the social and mental skills and autism characteristics in children with Fragile X Syndrome.
Continue Reading250,000 euros for research in Neurofibromatosis type 1
Neuro-oncologist Dr. Walter Taal and nurse specialist Sarah van Dijk from the neurology department of Erasmus MC received a check for 250,000 euros on October 30, 2020. The money will go to research into the genetic disorder neurofibromatosis type 1.
Continue ReadingStart Dup15q and CAMK2 expertise centers
Recently, two new expertise have been launched under ENCORE! We can now welcome patients with CAMK2 Syndrome and Dup15q Syndrome at our ENCORE expertise center.
Continue ReadingNEPTUNE study for Angelman Syndrome completed
ENCORE participated in the international NEPTUNE study of the pharmaceutical company OVID. Four Dutch children participated in the study. The desired number of participants has now been reached, so no more children are enrolled. We expect the first results in early 2021.
Continue ReadingNEPTUNE TRIAL
Phase 3 clinical study of the effect of the drug OV101 (Gaboxadol) in children with Angelman Syndrome
Continue ReadingEXCEL TRIAL
Phase 2 and 3 clinical study of the effect of Lamotrigine on cognition in patients with NF1
Continue Reading